Google graduates its life sciences division; How will AbbVie use its FDA review voucher?;

@FierceBiotech: Baxalta bets on 'external innovation' to meet its $8.5B goal and ward off Shire. Article | Follow @FierceBiotech

@JohnCFierce: In a first for diabetes, Lilly and Boehringer's Jardiance prevents heart attacks, strokes in trial. FiercePharma story | Follow @JohnCFierce

@DamianFierce: Turing has a new Form D reflecting that $90M claim but now including warrants and a loan. SEC form | Follow @DamianFierce

> Google ($GOOG), as part of its Alphabet evolution, is turning its life sciences segment into a standalone division, bringing it out of the Google X umbrella under CEO Andrew Conrad. More

> What's AbbVie ($ABBV) going to do with the $350 million FDA shortcut it bought this week? EP Vantage considers whether the company should accelerate filgotinib, a next-generation rheumatoid arthritis treatment. Item

> Former President Jimmy Carter, diagnosed with melanoma that has spread to the brain, is receiving Merck's ($MRK) immunotherapy Keytruda. News

Medical Device News

@FierceMedDev: IYCMI yesterday: Startup nabs $5.3M to back 2015 launch for connected fertility thermometer, app. Article | Follow @FierceMedDev

@VarunSaxena2: Cannabics Pharma's extended-release medical marijuana capsules available in Colorado. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Lilly faces patent-infringement fight over 'Take-n-Slide' drug adherence tool. More from FiercePharma | Follow @EmilyWFierce

> Gauss raises $3.3M for real-time surgical blood loss monitoring system, iPad app. More

> Patient monitoring company expanding in Milwaukee, adding 150 jobs. Article

Pharma News

@FiercePharma: Beef producers lash out at USDA's choice of Humane Society vet for advisory panel. FierceAnimalHealth article | Follow @FiercePharma

@EricPFierce: Mylan recalls more of the cancer meds made at Indian plants hit with FDA warning letter. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Purdue hones abuse-deterrent edge with painkiller safety campaign. FiercePharmaMarketing story | Follow @CarlyHFierce

> Nervous drugmakers await decision on Bass' Ampyra patent challenge. More

> Majority across political spectrum in U.S. favor government steps to cut drug prices. Article

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.